Investing.com - Edesa Biotech (NASDAQ: EDSA) reported third quarter EPS of $-0.1000, $0.07 better than the analyst estimate of $-0.1733. Revenue for the quarter came in at $0.00...
Investing.com - Edesa Biotech (NASDAQ: EDSA) reported first quarter EPS of $-0.170, $0.02 better than the analyst estimate of $-0.190. Revenue for the quarter came in at $0.00...
Investing.com - Edesa Biotech (NASDAQ: EDSA) reported first quarter EPS of $-0.395, in line with the analyst estimate of $-0.395. Revenue for the quarter came in at $0.00 versus...
Investing.com – U.S. stocks were mixed after the close on Tuesday, as gains in the Oil & Gas, Healthcare and Technology sectors led shares higher while losses in the Telecoms,...
Investing.com – U.S. stocks were lower after the close on Monday, as losses in the Oil & Gas, Basic Materials and Technology sectors led shares lower. At the close in NYSE, the...
Edesa Biotech, Inc. (EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced favorable final results from a Phase...
Investing.com – U.S. stocks were higher after the close on Friday, as gains in the Oil & Gas, Basic Materials and Industrials sectors led shares higher. At the close in NYSE, the...
Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that Health Canada has approved...
Edesa Biotech, Inc. (EDSA) today announced it has entered into a binding commitment letter in respect of a $10 million revolving credit facility agreement with Dr. Par Nijhawan,...
Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, has secured a commitment of up to C$23 million...